Financial performance
The year 2006 was another solid growth year for Novo Nordisk. Sales of our key products went well in all major markets, driven by the modern insulins. At the same time significant efficiency gains in production made it possible to invest more in research and development of new drugs as well as sales and marketing efforts. Across the organisation people are reinforcing the company's position as a values-based business.
More information about the financial performance of Novo Nordisk:
Download the stock exchange announcement: Full-year results 2006
Download the consolidated financial and non-financial statements from the Annual Report 2006 (PDF).
Go to the Investor section on novonordisk.com.
This page has been assessed by PricewaterhouseCoopers as part of its assessment of Novo Nordisk’s statement that it reports ‘in accordance’ with GRI. Please refer to Audit and assurance for a full description of the nature of assurance offered.
